{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:06Z","timestamp":1786120206597,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D\n                      <jats:sub>2<\/jats:sub>\n                      receptors. Because of its partial agonist activity, it was believed that aripiprazole would be less susceptible than typical antipsychotics to induce extrapyramidal side effects. However, a few case-reports and case-series detailing aripiprazole-induced movement disorders have been published, suggesting that aripiprazole-induced movement disorders may arise. Here, we seek to report further cases of aripiprazole-induced movement disorders to raise the awareness of clinicians on this adverse effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients referred to the Andr\u00e9-Barbeau Movement Disorder clinic treated with aripiprazole were enrolled in this study. Their charts were retrospectively reviewed and data regarding past psychiatric history, past antipsychotic medication, duration of aripiprazole treatment, daily dose of aripiprazole administered, and resulting movement disorders were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We report 14 cases of parkinsonism, tardive dyskinesia and akathisia induced by aripiprazole. Some of these, mostly the parkinsonian phenotype, abated spontaneously following drug discontinuation, whereas others, mostly related to tardive phenomena, persisted after aripiprazole was discontinued, and required treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This case-series adds to the existing literature that suggests that movement disorders may arise following treatment with aripiprazole. Clinicians should be aware of this potential side effect when prescribing aripiprazole to patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/nrl.0000000000000096","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T20:36:15Z","timestamp":1482611775000},"page":"24-28","source":"Crossref","is-referenced-by-count":20,"title":["Movement Disorders Induced by the \u201cAtypical\u201d Antipsychotic Aripiprazole"],"prefix":"10.1097","volume":"22","author":[{"given":"Karim","family":"Selfani","sequence":"first","affiliation":[{"name":"Unit\u00e9 des Troubles du Mouvement Andr\u00e9 Barbeau"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie L.","family":"Soland","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Troubles du Mouvement Andr\u00e9 Barbeau"},{"name":"Division of Neurology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al"},{"name":"Neuroscience"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chouinard","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Troubles du Mouvement Andr\u00e9 Barbeau"},{"name":"Division of Neurology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al"},{"name":"Neuroscience"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Troubles du Mouvement Andr\u00e9 Barbeau"},{"name":"Division of Neurology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al"},{"name":"Pharmacology, Universit\u00e9 de Montr\u00e9al"},{"name":"Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230929","first-page":"36","article-title":"Antipsychotic-induced movement disorders: evaluation and treatment","volume":"2","author":"Mathews","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"key":"R2-20230929","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11940-009-0019-3","article-title":"Drug-induced parkinsonism","volume":"11","author":"Susatia","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"R3-20230929","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2147\/DDDT.S32328","article-title":"New and emerging treatments for symptomatic tardive dyskinesia","volume":"7","author":"Rana","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"R4-20230929","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/mds.26467","article-title":"Neuroleptic-induced Parkinsonism: clinicopathological study","volume":"31","author":"Shuaib","year":"2016","journal-title":"Mov Disord"},{"key":"R5-20230929","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5334\/tohm.165","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (NY)"},{"key":"R6-20230929","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","article-title":"Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology","volume":"10","author":"Davies","year":"2004","journal-title":"CNS Drug Rev"},{"key":"R7-20230929","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1176\/appi.neuropsych.12030069","article-title":"Reversal of aripiprazole-induced tardive akathisia by addition of pregabalin","volume":"25","author":"De Berardis","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R8-20230929","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0004867412461058","article-title":"Aripiprazole induced tardive dyskinesia\u2014accruing evidence","volume":"47","author":"Alexander","year":"2013","journal-title":"The Australian and New Zealand journal of psychiatry"},{"key":"R9-20230929","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pnpbp.2009.03.023","article-title":"Courses of aripiprazole-associated tardive dyskinesia: report of two cases","volume":"33","author":"Wang","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R10-20230929","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1176\/ajp.2006.163.6.1112a","article-title":"Aripiprazole-induced acute dystonia","volume":"163","author":"Desarkar","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R11-20230929","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.23402","article-title":"Tardive dyskinesia and other movement disorders secondary to aripiprazole","volume":"26","author":"Pena","year":"2011","journal-title":"Mov Disord"},{"key":"R12-20230929","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3109\/00207450903225553","article-title":"Movement disorders associated with aripiprazole use: a case series","volume":"119","author":"Hall","year":"2009","journal-title":"Int J Neurosci"},{"key":"R13-20230929","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry"},{"key":"R14-20230929","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/PRA.0000000000000124","article-title":"Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and\/or dystonia in patients with major depressive disorder, Part 2: preclinical and early phase human proof of concept studies","volume":"22","author":"Macaluso","year":"2016","journal-title":"J Psychiatr Pract"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00127893-201701000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:25:58Z","timestamp":1786047958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00127893-201701000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/nrl.0000000000000096","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}